Get the Stockscreener App
0.732
0.11%
0.0008
Iterum Therapeutics Plc stock is traded at $0.732, with a volume of 496.44K.
It is up +0.11% in the last 24 hours and down -24.89% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.7312
Open:
$0.75
24h Volume:
496.44K
Relative Volume:
0.78
Market Cap:
$29.28M
Revenue:
-
Net Income/Loss:
$-35.58M
P/E Ratio:
-0.2762
EPS:
-2.65
Net Cash Flow:
$-42.82M
1W Performance:
-8.79%
1M Performance:
-24.89%
6M Performance:
-54.25%
1Y Performance:
-37.44%
1-Day Range:
$0.72
$0.76
1-Week Range:
$0.72
$0.838
52-Week Range:
$0.72
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.732 | 29.25M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Intraday pattern recognizer results for Iterum Therapeutics plcDaily Stock Movement Forecast with Accuracy - Newser
How to forecast Iterum Therapeutics plc trends using time seriesHigh Reward Investment Strategy for Beginners - Newser
Real time pattern detection on Iterum Therapeutics plc stockConsistent Gain Plan with AI Support - Newser
Is Iterum Therapeutics plc showing signs of accumulationWeekly Hot Stocks Based on Volume Flow - Newser
Iterum Therapeutics plc Company Revenue and Profit Trends: A Deep DiveFree Real Profit Trade Plan Suggestions - Newser
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcFree Short Term Setup With Predictive Chart - Newser
What moving averages say about Iterum Therapeutics plcShort Term Gain Strategy with AI Logic - Newser
Is Iterum Therapeutics plc a growth stock or a value stockChart Pattern Growth Plan For Smart Trading - jammulinksnews.com
Does Iterum Therapeutics plc stock perform well during market downturnsSwing Trade Alerts That Work - jammulinksnews.com
How to use a screener to detect Iterum Therapeutics plc breakoutsPortfolio Review Summary with Five-Year Outlook - Newser
Price momentum metrics for Iterum Therapeutics plc explainedPattern Recognition Based Market Move Prediction - Newser
What catalysts could drive Iterum Therapeutics plc stock higher in 2025Stock Strategy Target Finder From AI Tools - jammulinksnews.com
What are the technical indicators suggesting about Iterum Therapeutics plcRetirement Planning Insights For 2025 - jammulinksnews.com
Iterum Therapeutics to Announce Q2 2025 Earnings on Aug 5, 2025 - AInvest
Using Ichimoku Cloud for Iterum Therapeutics plc technicalsFast Return Equity Trade Forecast Points to Small Caps - metal.it
Why Iterum Therapeutics plc stock attracts strong analyst attentionSmart Forecast Signals from AI Models - Newser
Iterum Therapeutics plc Price Holds Above Key Fib LevelAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Best data tools to analyze Iterum Therapeutics plc stockFree Fundamental Winners With Safe Entry Plan - Newser
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 - The Manila Times
Antibiotics Developer Iterum Therapeutics Announces Q2 2025 Earnings Date: Key Details Inside - Stock Titan
What makes Iterum Therapeutics plc stock price move sharplyFree Alpha Driven Watchlist With Alerts - Newser
How strong is Iterum Therapeutics plc company’s balance sheetMarket Forecast Target Finder For 2025 - jammulinksnews.com
What is the dividend policy of Iterum Therapeutics plc stockMaximize gains with data-driven stock picks - jammulinksnews.com
What are analysts’ price targets for Iterum Therapeutics plc in the next 12 monthsUnmatched market performance - jammulinksnews.com
Earnings Chart Overlay Points to Iterum Therapeutics plc UpsideFast Entry High Potential Stock Alerts Triggered - metal.it
What institutional investors are buying Iterum Therapeutics plc stockUnlock daily stock market insights for success - jammulinksnews.com
Iterum Therapeutics plc Stock Analysis and ForecastFree Stock Market Trend Analysis - PrintWeekIndia
Is Iterum Therapeutics plc a good long term investmentSuperior risk-adjusted returns - Autocar Professional
What drives Iterum Therapeutics plc stock priceConsistently exceptional gains - Autocar Professional
Iterum Therapeutics Plc (ITRM) Stock: A Year of Market Movement, Down and Up - investchronicle.com
What analysts say about Iterum Therapeutics plc stockHigh-profit capital plays - jammulinksnews.com
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):